Additional file 1 of A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres

Additional file 1: Table S1. Sample counts and median telomeric content per disease group. Table S2. Telomeric content of samples (pan-cancer) with alterations in ATRX, DAXX, TERC, TERTp, or WT. Table S3. Hits from enrichment analysis of high telomeric content samples with genetic alterations per disease ontology. Table S4. Telomeric content of samples (within specific disease ontologies) with alterations in ATRX, DAXX, TERC, TERTp, RAD21, or HGF compared to WT. Table S5. In each tab, a summary of alterations observed in ATRX, DAXX, TERC, TERTp, RAD21, and HGF is provided. SV, short variant alteration; CN, copy number alteration; RE, rearrangement. For SVs, the protein effect is listed and for REs, the partner gene is noted. Table S6. Top five disease ontologies in terms of RAD21 alteration prevalence. Table S7. Telomeric content of samples (pan-cancer) with alterations in ATRX, DAXX, TERC, TERTp, RAD21, HGF, or WT. Table S8. Count of samples with alterations vs. amplifications in RAD21 and HGF. Table S9. Hits from enrichment analysis of high telomeric content samples in amplifications across chr8q chromosome bands. Table S10. Levels of TERRA in samples (pan-cancer) with alterations in ATRX, DAXX, RAD21, HGF, or WT. Table S11. Telomeric content of samples with multiple alterations in ATRX, DAXX, TERC, TERTp, RAD21, or HGF (within specific disease ontologies).